No 2027 premium has been published for any individual Medicare drug plan, and none will be until federal officials release the plan landscape in September. What has already been settled is a subtraction. On July 28, 2026, the Centers for Medicare and Medicaid Services announced that the Part D Premium Stabilization Demonstration, the voluntary program that has held down stand-alone prescription drug plan premiums since 2025, will not continue past the end of this calendar year. The bids that determine what 2027 plans look like were built without it.
What the Part D Premium Stabilization Demonstration paid for
The demonstration was never a discount coupon sent to households. It was a set of payment adjustments made to insurers, on the theory that plans holding steadier prices would keep the market from lurching. It had three parts. CMS applied a uniform reduction of $15 to the base beneficiary premium used to calculate a plan’s basic premium for every participating stand-alone drug plan. It imposed a year-over-year limit so that a plan’s total premium could not rise more than $35 from the prior year. And it narrowed the risk corridors, shifting a larger share of a plan’s potential losses onto the government.
The reason CMS gave at the time was market disruption. The Inflation Reduction Act rebuilt the Part D benefit for 2025, capping enrollee out-of-pocket drug spending at $2,000, eliminating the coverage gap, and moving much of the government’s subsidy from back-end reinsurance into an upfront payment that left plans carrying more liability. CMS said it had observed far more variation in stand-alone drug plan bids than in Medicare Advantage drug plan bids, and that the variation could trigger disruptive enrollment shifts while the redesign settled in. The demonstration was structured as voluntary but nationwide, designed so that every stand-alone sponsor would take part.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
The reason CMS gave for stopping at the close of CY 2026
The July announcement frames the end of the program as a return to normal rather than a cut. For contract year 2027, the agency said, its analysis of the bids indicates that Part D plan sponsors had sufficient experience under the redesigned Part D benefit to support their assumptions in developing prescription drug plan bids. On that basis, CMS said it will discontinue the demonstration at the end of CY 2026 to return the program to operating under traditional market conditions in CY 2027.
What the announcement does not do is put a number on the consequence. CMS published no estimate of what the change means for any individual enrollee, no average dollar increase, and no percentage. Anyone circulating a specific per-person figure for 2027 is working from a projection or an outside estimate rather than from the agency’s own announcement. The honest reading is that a support beam is being removed from how stand-alone drug plans are priced, and the plan-by-plan result is not yet public.
The $296.05 national average bid amount is not a premium
The same July announcement carried the technical figures that plan sponsors work from. For 2027, the national average monthly bid amount will be $296.05, and the de minimis amount will be $2. The national average bid is an enrollment-weighted average of all applicable Part D plan bids for basic benefits, weighted by how many enrollees each plan has, and its purpose is to calculate the government’s subsidy to plans.
It is worth saying plainly what that number is not, because the figure is large enough to alarm someone who mistakes it for a price tag. CMS made the point directly when it launched the demonstration in 2024: an increase in the national average bid does not mean Part D premiums will rise by a similar amount, because a significant portion of the bid represents money moving from back-end reinsurance into the upfront government subsidy paid to plans. A reader looking for what a plan will actually charge will not find it in the bid amount.
The 2027 plan-level numbers arrive in September
CMS said in the same document that it will release the 2027 Medicare Advantage and Part D landscape in mid-to-late September, once all offerings are finalized, and that final average premiums and other key information will come out at the same time. That is the first point at which a specific drug plan’s 2027 price becomes a published fact rather than a forecast.
A second document lands in the same stretch of the calendar, and it is plan-specific rather than national. Every Medicare plan sends its members an Annual Notice of Change each fall, which Medicare says arrives in September and lists the changes in coverage and costs that take effect in January. Medicare’s instruction for that notice is short: review the changes and decide whether the plan will still meet the household’s needs next year, and contact the plan if the notice never shows up. Open Enrollment then runs October 15 through December 7, with changes effective January 1.
Stand-alone drug plans, not Medicare Advantage drug coverage
The demonstration applied only to stand-alone prescription drug plans, the separate Part D coverage bought by people who stay in Original Medicare, including employer group waiver plans. CMS limited it to that corner of the market on purpose, explaining that variation in stand-alone bids was much greater than in Medicare Advantage drug plan bids, partly because Medicare Advantage plans can apply rebate dollars that further reduce what their members pay for drug coverage.
That boundary determines who is actually looking at a changed pricing environment for 2027. A household in Original Medicare with a separate drug plan sits in the market where the cushion is being withdrawn. A household whose drug coverage is bundled inside a Medicare Advantage plan was never inside the demonstration to begin with. CMS’s own description of what happens next is narrow and precise, and it is the sentence worth holding on to until September: the demonstration ends at the close of CY 2026, and 2027 returns to traditional market conditions.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
